

**SALE OF SHARES BY DIRECTOR AND SUBSTANTIAL SHAREHOLDER**

---

The Board of Directors (the "**Board**") of AsiaMedic Limited (the "**Company**") wishes to announce that it has today been informed by Grandiflora Pte. Ltd. ("**Grandiflora**") and Mr. Tan Wang Cheow (collectively the "**Vendors**" and each a "**Vendor**") that the Vendors have today entered into a sale and purchase agreement with Luye Medicals Group Pte. Ltd. (the "**Purchaser**") pursuant to which the Vendors have agreed to sell, and the Purchaser has agreed to purchase, an aggregate of 95,431,396 ordinary shares representing approximately 28.15% of the issued and paid-up share capital of the Company at a price of \$0.18 per share. The Vendors have further informed the Board that the sale and purchase of the abovementioned shares is expected to be completed on 3 June 2015 (the "**Completion**").

The Board has also been informed that upon Completion:

- (a) Grandiflora will cease to be a substantial shareholder of the Company; and
- (b) Grandiflora and Mr Tan Wang Cheow will cease to be shareholders of the Company altogether.

Further, the Board has been notified that:

- (a) Mr Tan Wang Cheow will resign as a Director of the Company with effect from 3 June 2015; and
- (b) Grandiflora's nominees to the Board, Mr Andi Solaiman and Ms Suzanne Liau will resign as Directors of the Company with effect from 3 June 2015.

In addition, the Vendors have requested the Board to consider 3 nominees of the Purchaser, Dr Hong Hai (Independent Director), Mr Tan Soo Kiat (Non-Executive Director) and Mr Koh Boon How (Kenneth) (Alternate to Mr Tan Soo Kiat) for appointment as Directors of the Company upon Completion. The Nominating Committee of the Company and the Board have considered the request, and after deliberation, it was resolved that the appointments be effective from Completion.

The Company will make further announcements on the above matters at the appropriate junctures.

**BY ORDER OF THE BOARD**

**Ms Foo Soon Soo**  
**Company Secretary**

2 June 2015

*This announcement has been prepared by the Company and reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.*

*Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd)  
Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805  
Telephone number: (65) 6319 4954*